An interventional study of Dehydrated human amnion/chorion membrane and Standard of Care in Partial Nephrectomy, Kidney Cancer and Renal Function Aggravated, sponsored by MiMedx Group, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-13.
Sponsored by MiMedx Group, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 551 studies in Kidney Neoplasms with a site in United States — 67 open to participants now, 109 under way, 4 of them phase 3. Kidney Neoplasms · United States.
Among the 551 studies in Kidney Neoplasms with a site in United States, this one is the 148th largest by enrollment of the 443 interventional ones that give a count, is one of 26 that started in 2017, is one of 58 with no phase, and was the 415th registered.
969 studies on the registry are indexed under Kidney Neoplasms; 210 are open to participants now.
Browse Kidney Neoplasms studies →67 of the 551 studies in Kidney Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Henry Ford Health System · Sites in United States
Ages 18–75
Henry Ford Health System · Sites in United States
Ages 18–75
NYU Langone Health · Sites in United States
Ages 18+
PeptiDream Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 173 Kidney Neoplasms studies recruiting now, 133 (77%) set no upper age limit and 15 (9%) stop at 75 or younger; 20 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
551 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 188 · Phase 2 259 · Phase 3 31 · Phase 4 6
First in 1990; this study’s year is marked. 26 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is above the median of 46 across 668 interventional studies indexed under Kidney Neoplasms.
Median enrollment 37 across the 443 interventional studies, 350 across the 62 observational. Of the 410 that completed or were terminated, 157 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
154 of 551 have an industry lead sponsor. The 10 most frequent:
MiMedx Group, Inc. is the lead sponsor of 35 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
MiMedx Group, Inc. has 1 study filed under Kidney Neoplasms — fewer than ten, so there is no comparison to draw.
41 of the studies in Kidney Neoplasms with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07814872Harvard Medical School (HMS and HSDM)A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment | 2026-11 |
| NCT06234605HiberCell, Inc.A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma | 2026-11 |
| NCT00582621Memorial Sloan Kettering Cancer CenterAscertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders | 2026-12 |
| NCT06964958Dana-Farber Cancer Institute177LuPSMA in Renal Cell Carcinoma | 2026-12-01 |
| NCT05468697Merck Sharp & Dohme LLCA Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024) | 2026-12-22 |
Add all 41 to your calendar (.ics) → With an account.
Among the 551 studies in Kidney Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
After partial nephrectomy, kidney function decreases by about 10% overall and by about 20% in the operated kidney. This is primarily due to the loss of healthy parenchymal volume during resection of the tumor. In an effort to preserve and regenerate healthy parenchyma during the procedure and ultimately renal function after partial nephrectomy, the single center double arm single-blinded randomized screening clinical trial will evaluate the ability of human amnion/chorion allograft to facilitate the recovery of renal function following robotic partial nephrectomy.
To determine whether Amniofix facilitates improved recovery of renal function at 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Partial nephrectomy patched with DHACM
Other: Dehydrated human amnion/chorion membrane
Partial nephrectomy without DHACM.
Other: Standard of Care
dehydrated human amnion/chorion membrane
Standard of Care
Recovery of Renal Function
Evaluation of GlomerularFiltration Rate (GFR)
Time frame: 12 months
Preservation of Renal Parenchymal Volume
Using radiologic computed tomography measurements
Time frame: 12 months
Cancer Control Rates
Observed recurrence rate
Time frame: 12 months
Ran from May 2017 to primary completion in Feb 2019, 20 months.
Of 97 interventional studies with no phase under Kidney Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 90. This study's 20 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.